EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

Szczegóły
Opis

Tytuł:: EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%
Autorzy:: Paul Zarogoulidis
Panos Chinelis
Christofors Efthymiou
Anastasia Athanasiadou
Vasilis Mpikos
George Papatsibas
Vasilis Papadopoulos
Elena Maragouli
Haidong Huang
Georgia Trakada
Anastasios Kallianos
Lemonia Veletza
Wolfgang Hohenforst-Schmidt
Temat:: Adenocarcinoma
NSCLC
Epidermal growth factor
Anaplastic lymphoma kinase
Programmed death-ligand 1
Diseases of the respiratory system
RC705-779
Źródło:: Respiratory Medicine Case Reports, Vol 22, Iss C, Pp 7-10 (2017)
Wydawca:: Elsevier, 2017.
Rok publikacji:: 2017
Kolekcja:: LCC:Diseases of the respiratory system
Typ dokumentu:: article
Opis pliku:: electronic resource
Język:: English
ISSN:: 2213-0071
Relacje:: http://www.sciencedirect.com/science/article/pii/S2213007117301685; https://doaj.org/toc/2213-0071
DOI:: 10.1016/j.rmcr.2017.05.010
Dostęp URL:: https://doaj.org/article/f4ec2194c18e4594911fe93508c5611e Link otwiera się w nowym oknie
Numer akcesji:: edsdoj.f4ec2194c18e4594911fe93508c5611e
: Czasopismo naukowe

Full Text Finder

Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression.

Informacja